Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: caladrius.com
Brookline Capital Management reiterated coverage of Caladrius Biosciences with a rating of Buy and set a new price target of $10.00 from $7.00 previously
Brookline Capital reiterated coverage of Caladrius Biosciences with a rating of Buy and set a new price target of $10.00 from $7.00 previously
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the appointment of Todd Girolamo to its Board of Directors. Girolamo is a seasoned attorney and biopharmaceutical executive specializing in health-related products, currently serving as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary for Caladrius Biosciences, Inc. (NASDAQ:CLBS). "Mr. Girolamo will bring invaluable legal, finance and biopharmaceutical development insight and leadership to our Board," said
BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Company's Chief Medical Officer ("CMO"). Dr. Buck joins Caladrius from ICON plc ("ICON"), a global provider of drug and device development and commercialization services to the pharmaceutical, biotechnology and medical device industries. During her time at ICON, Dr. Buck served as its CMO, where she represented the company's position on key scientific, ethical, and medical govern
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today announced the appointment of Joseph Talamo as chief financial officer and the promotion of Ari Nowacek, M.D., Ph.D., to chief business officer. "We're pleased to welcome Joe to the HiberCell team and have Ari take on an expanded role as chief business officer," said Alan C. Rigby, Ph.D., co-founder and chief executive officer of HiberCell. "Joe has a track record of successful financial leadership and we're pleased to have him on board during a tremendous period of organizational growth. As a co-founder o
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L
SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
SC 13G - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
SC 13G - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
SC 13G - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
SC 13G - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
SC 13G - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "The second quarter of 2022 was a transformative and energizing quarter for Caladrius with the announcement of our
BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three and six months ended June 30, 2022, on Thursday, August 4, 2022, at 4:30 p.m. (EDT). The Company is utilizing a new conference call service. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details for dial-in options. To avoid d
Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA® to be announced by year-end 2022 following regulatory and business review Caladrius Management will host a conference call tomorrow, May 24th at 8:15 a.m. EDT BASKING RIDGE, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company has suspended patient enrollment in its Phase 2b study of XOWNA®, known as
BASKING RIDGE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months ended March 31, 2022, on Thursday, May 5, 2022 at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below. Dial-in information: Conference ID: 7129748U.S. Toll-Free: 866-595-8403International: 706-758-9979 Please dial-in 10 minutes before the start of the conference call. A live webcast of th
Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong existing partnerships and potential for future attractive partnerships Lisata to combine development pipelines from both companies with an emphasis on advancing Cend's CendR Platform™ technology products in a range of solid tumor oncology indications The merged company projects a number of potential value-creating data and business development milestones over the next 24 months Caladrius to make an immediate investment of $10 million in Cend in connection with a development collaboration agreement
BASKING RIDGE, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, provides a business update and reports financial results for the three and twelve months ended December 31, 2021. "Caladrius made significant progress in 2021 that we believe has positioned us well to achieve several important milestones in 2022," stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius. "Highlights from 2021 include the initiation of our ongoing Phase 2b FREEDOM Trial of XOWNA® for the
BASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months and twelve months ended December 31, 2021, on Tuesday, March 22, 2022, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below. Dial-in information: Conference ID: 5066195U.S. Toll-Free: 866-595-8403International: 706-758-9979 Please dial-in 10 minutes before the start of the conference call
Company Reports Strong Cash Position as it Prepares to Initiate a CD34+ Cell Therapy Study in Diabetic Kidney Disease Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, provides a corporate update and reports financial results for the three and nine months ended September 30, 2021. "Caladrius continued to advance and optimize its development programs in the third quarter despite the ongoing challenges to clinical devel
BASKING RIDGE, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended September 30, 2021, on Thursday, November 4, 2021, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below. Dial-in information: Conference ID: 8378269U.S. Toll-Free: 866-595-8403International: 706-758-9979 A live webcast of the call will be available on the Caladrius website under the Investors &
BASKING RIDGE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three and six months ended June 30, 2021. "The second quarter and first six months of 2021 have proven to be operationally and financially positive for Caladrius. Despite the continuing challenges presented by the COVID-19 pandemic, we continued to advance and expand our clinical pipeline while also adding a large amount of additional capital to our balance sheet," stated Davi
Company to commence trading on The Nasdaq Capital Market under Ticker Symbol "LSTA" Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing seasoned biopharmaceutical and clinical development industry executives BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius") and Cend Therapeutics, Inc. ("Cend") today announced that the proposed merger of the two companies has closed following the approval of Caladrius' stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganization, dated as of April 26, 2022, by and among Caladrius and Cend Therapeutics ("Cend"), and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius' common stock to Cend's stockholders pursuant to the Agreement and Plan of Merge
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events: H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)Location: Lotte New York Palace Hotel in New York City (Hybrid conference)Presentation format: In-person and live/archived webcastPresentation Date/Time: Wednesday, September 14, 2022, at 12:00 p.m. ESTWebcast Link: https://bit.ly/3ARcXnjFor m
Study to be part of Roche's Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius' initial investment in Cend BASKING RIDGE, N.J. and SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company") and Cend Therapeutics, Inc. ("Cend"), today announced Cend's execution of a collaboration agreement with F. Hoffmann-La Roche Ltd. ("Roche") to evaluate Cend's lead investigational drug, CEND-1, in combination with atezolizumab (Tecentriq®), Roche's PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients wit
Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "The second quarter of 2022 was a transformative and energizing quarter for Caladrius with the announcement of our
BASKING RIDGE, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, announced today the completion of enrollment and dosing in its Phase 1b, open-label, proof-of-concept study of CLBS201, a CD34+ regenerative cell therapy investigational product for intra-renal artery administration, for the treatment of diabetic kidney disease ("DKD"). The Company expects to announce top-line data from all subjects by the first quarter of 2023. "We are pleased to announce that we have treated the last subject in our Phase 1b clinical
BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three and six months ended June 30, 2022, on Thursday, August 4, 2022, at 4:30 p.m. (EDT). The Company is utilizing a new conference call service. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details for dial-in options. To avoid d
BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, and Cend Therapeutics, Inc. ("Cend"), a privately-held, clinical-stage drug discovery and development company developing a novel approach to enable more effective treatments for solid tumor cancers, pursuant to a collaboration agreement entered into by each company in connection with their recently announced and pending merger to form Lisata Therapeutics, today announced that The Lancet Gastroenterology and Hepatology has published data f
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. ("Cend") today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend's lead investigational drug, in patients with first-line metastatic pancreatic ductal adenocarcinoma. The ASCEND trial is a 125-patient, double-blind, randomized, placebo-controlled clinical trial, and is being conducted at up to 40 sites in Australia and New Zealand. Designed and led by the Australasian Gastro-Intestinal Trials Group ("AGITG") in collaboration with the NHMRC Clinical Trial Centre at the University of Sydney, Cend will provide funding, study drug and regulatory support. "Building on the encouraging saf
BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, announces that its merger partner in the creation of Lisata Therapeutics ("Lisata"), Cend Therapeutics, Inc. ("Cend") today indicated that the first patient has been treated in the Phase 2b study of CEND-1 in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma. The ASCEND trial is a 125-patient, double-blind, randomized, placebo-controlled clinical trial being
10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
S-8 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
8-K/A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
8-K/A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
424B5 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
8-K - CALADRIUS BIOSCIENCES, INC. (0000320017) (Filer)
8-K - CALADRIUS BIOSCIENCES, INC. (0000320017) (Filer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
Gainers AMTD Digital Inc. (NYSE:HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news. Avenue Therapeutics, Inc. (NASDAQ:ATXI) surged 53.2% to close at $0.3562. AMTD IDEA Group (NYSE:AMTD) surged 50% to close at $1.95 on Wednesday. Aileron Therapeutics, Inc. (NASDAQ:ALRN) rose 42.2% to settle at $0.2702. Aileron Therapeutics, last month, posted a Q2 loss of $0.09 per share. Dawson Geophysical Company (NASDAQ:DWSN) gained 40.2% to close at $1.57. Akerna Corp. (NASDAQ:KERN) shares gained 26.9% to close at $0.1650 on Wednesday after gaining 8% on Tuesday. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM
Gainers Avenue Therapeutics (NASDAQ:ATXI) stock rose 77.1% to $0.41 during Wednesday's regular session. Avenue Therapeutics's stock is trading at a volume of 56.8 million shares as of 13:30 EST. This is 18245.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.0 million. bioAffinity Technologies (NASDAQ:BIAF) stock increased by 51.64% to $6.28. The current volume of 42.3 million shares is 800.8% of bioAffinity Technologies's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $17.1 million. NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 2
During Wednesday's session, 265 companies made new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Alphabet (NASDAQ:GOOG) was the largest company by market cap to set a new 52-week low. First Wave BioPharma (NASDAQ:FWBI) was the smallest firm on a market cap basis to set a new 52-week low. Vintage Wine Estates (NASDAQ:VWE) shares dropped the most, trading down 43.13% to reach its new 52-week low. Westrock Coffee (NASDAQ:WEST) saw the sharpest rebound, as shares ascended 0.0%, reversing after hiting a new 52-week low. Stocks that set new 52-week lows on Wednesday are as follows: Alphabet (NASDAQ:GOOG) stock hit $104.50 on Wednesday morning, setting a new 52-week low
Gainers Akerna Corp. (NASDAQ:KERN) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday. SciSparc Ltd. (NASDAQ:SPRC) gained 68% to $1.3101 after the company announced it entered into an agreement to acquire Wellution for $20 million. bioAffinity Technologies, Inc. (NASDAQ:BIAF) shares jumped 51.2% to $6.27 after the company announced publication of its research in high-throughput flow cytometry analysis of sputum in PLOS ONE. My Size, Inc. (NASDAQ:MYSZ) rose 44% to $0.3194. ThermoGenesis Holdings, Inc. (NASDAQ:THMO) surged 36.8% to $0.3090. Avenue Therapeutics, Inc. (NASDAQ:ATXI) jumped 28.6% to $0.2992. Fast Radius, Inc. (NASDAQ:FSRD) gained 23.6% to $0.6799. NeuroOne Medical
BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganization, dated as of April 26, 2022, by and among Caladrius and Cend Therapeutics ("Cend"), and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius' common stock to Cend's stockholders pursuant to the Agreement and Plan of Merger
Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 21.6% to $10.09 during Friday's pre-market session. The company's market cap stands at $40.4 million. Biote (NASDAQ:BTMD) stock moved upwards by 14.51% to $5.05. The market value of their outstanding shares is at $38.2 million. WAVE Life Sciences (NASDAQ:WVE) shares moved upwards by 13.94% to $3.35. The market value of their outstanding shares is at $290.8 million. Meihua Intl Medical Techs (NASDAQ:MHUA) stock increased by 10.94% to $5.27. The market value of their outstanding shares is at $126.1 million. Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 9.89% to $1.42. The market value of their outstandi
Gainers NewAge, Inc. (NASDAQ:NBEV) shares rose 58.3% to $0.1935 in pre-market trading. NewAge shares tumbled around 47% on Thursday on continued weakness after the company recently announced it filed a voluntary petition for relief under chapter 11 of the United States Bankruptcy Code. biote Corp. (NASDAQ:BTMD) shares rose 31.3% to $5.79 in pre-market trading. Biote shares started trading after uplisting to the Nasdaq. bioAffinity Technologies, Inc. (NASDAQ:BIAF) rose 30.8% to $10.86 in pre-market trading after jumping 36% on Thursday. The company priced its IPO at $6.125 per unit. Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) rose 27% to $0.1170 in pre-market trading after declining arou
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vir Biotech Shuns FDA Submission Plans For GSK-Partnered COVID-19 Treatment In its Q2 earnings release, Vir Biotechnology Inc (NASDAQ:VIR) and its partner GSK plc (NYSE:GSK) said that they do not plan to file a marketing application for sotrovimab for COVID-19 at this time. The company also said it does not intend to pursue the U.S.-based Phase 3 COMET-STAR prophylaxis trial, citing evolving COVID-19 landscape and FDA discussions. Discussions with the FDA remain ongoing regarding the appropriate path forward for sotrovimab in the U.S. Aethlon Medical To Start Lab Studies For Hemopurifier F